0001437749-23-013125.txt : 20230508 0001437749-23-013125.hdr.sgml : 20230508 20230508215337 ACCESSION NUMBER: 0001437749-23-013125 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230425 FILED AS OF DATE: 20230508 DATE AS OF CHANGE: 20230508 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Plooster Matthew R CENTRAL INDEX KEY: 0001638364 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36913 FILM NUMBER: 23899726 MAIL ADDRESS: STREET 1: 2656 CROSSPARK ROAD STREET 2: SUITE 100 CITY: CORALVILLE STATE: IA ZIP: 52241 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ZEVRA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001434647 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205894398 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1180 CELEBRATION BOULEVARD, SUITE 103 CITY: CELEBRATION STATE: FL ZIP: 34747 BUSINESS PHONE: (321) 939-3416 MAIL ADDRESS: STREET 1: 1180 CELEBRATION BOULEVARD, SUITE 103 CITY: CELEBRATION STATE: FL ZIP: 34747 FORMER COMPANY: FORMER CONFORMED NAME: KEMPHARM, INC DATE OF NAME CHANGE: 20130530 FORMER COMPANY: FORMER CONFORMED NAME: KEMPHARM INC DATE OF NAME CHANGE: 20080507 4 1 rdgdoc.xml FORM 4 X0407 4 2023-04-25 0001434647 ZEVRA THERAPEUTICS, INC. ZVRA 0001638364 Plooster Matthew R C/O ZEVRA THERAPEUTICS, INC. 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747 1 0 Stock Option (right to buy) 5.59 2023-04-25 4 A 0 49200 0 A 2033-04-24 Common Stock 49200 49200 D The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, April 25, 2023. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's eighth amended and restated non-employee director compensation policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Matthew R. Plooster 2023-05-08